Loading

wait a moment

Randomized double-blind trial of the effects of humidified: RESULTS (2)

Of the 16 patients who withdrew, six stated a sense of increased dryness as the reason. Four others were unwell (“too tired”, etc), two became confused, two were “not interested”, one preferred dry oxygen and one had miscellaneous reasons.

Symptom and problem scores: The primary symptom of interest was nasal dryness. Mean symptom scores for nasal dryness (Figure 1) indicate a statistically significant decrease (P=0.018) in dryness symptoms in the humidification group relative to the nonhumidification group in the first period. This difference is characterized by a slight, insignificant increase in symptoms in the nonhumidified group compared with a significant decrease (P=0.002) in the humidified arm from baseline to day 1. The same pattern difference did not occur in the second period after treatment crossover, as evidenced by a statistically significant period-treatment interaction (P=0.043) (Figure 1).

A second measure of interest was nosebleed. Results (Figure 2) indicate a corresponding increase in the incidence of nosebleeds in the nonhumidified compared with the humidified groups, peaking at day 2, which did not, however, attain statistical significance (P=0.093). There were no statistically significant differences between treatments for the four other symptoms. The prevailing trend in both groups was towards decreased incidence of dry mouth and dry throat, and in headache and chest discomfort over the study (Table 2). In particular, mouth dryness (P=0.01), headache (P<0.0001) and chest discomfort (P=0.0001) showed marked decreases from baseline to the first day. Thereafter, the general trends over the study were downward and statistically significant, except for the symptom of headache. You will always be offered help allergies at the pharmacy you can trust.
Figure 1. Randomized double blind trial of the effects
Figure 1) Mean symptom scores for nasal dryness by day. Randomization groups are connected by lines. Treatment administered is denoted by ‘X’ for humidification, and by ‘0’ for nonhumidification. Scores: 0 = no discomfort; 1 = mild discomfort; 2 = some discomfort; 3 = moderate discomfort; 4 = worst possible discomfort

Figure 2. Randomized double blind trial of the effects
Figure 2) Prevalence of nosebleed (%) by day. Randomization groups are connected by lines. Treatment administered is denoted by ‘X’for humidification, and by ‘0’ for nonhumidification

Table 2. Incidence (per patient day) of symptoms (symptom score = 2) or problems (presence of nosebleed, cough, phlegm) in first period*

Nonhumidified Humidified
Day 0f Days 1-3 Day 0 Days 1-3
Dry nose (%) 41.5 40.9 40.9 29.1
Dry mouth (%) 60.6 53.0 63.4 50.2
Dry throat (%) 48.9 42.8 38.7 36.2
Headache (%) 19.1 11.7 26.9 16.4
Chest discomfort (%) 44.7 22.9 34.4 23.6
Nosebleed (%) 10.6 17.3 10.8 10.8
Cough (%) 76.6 80.4 86.0 78.4
Phlegm (%) 59.6 56.3 69.9 63.8

*Scores for dry nose, dry mouth, dry throat, headache and chest discomfort: 0 = no discomfort; 1 = mild discomfort; 2 = some discomfort; 3 = moderate discomfort; 4 = severe discomfort. Scale for nosebleed, cough, phlegm: yes or no. fDay 0 is baseline day

Leave a Reply

Your email address will not be published. Required fields are marked *